Yiwei Lin

Yiwei Lin

Auto-generated profile, based on publicly available information

Yiwei Lin

Department of Translational Medicine, Jacobio (US) Pharmaceuticals, Inc., Burlington, Massachusetts

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYadi Wu
Yadi Wu
YWYu Wang
Yu Wang
YLYiwei Lin
Yiwei Lin
YLYajuan Liu
Yajuan Liu
YWYifan Wang
Yifan Wang
BZBinhua P. Zhou
Binhua P. Zhou
Snail1, a key transcription factor of epithelial–mesenchymal transition (EMT), is subjected to ubiquitination and degradation, but the mechanism by which Snail1 is stabilized in tumours remains unclear. We identify Dub3 as a bona fide Snail1 deubiquitinase, which interacts with and stabilizes Snail1. Dub3 is overexpressed in breast cancer; knockdown of Dub3 resulted in Snail1 destabilization, suppressed EMT and decreased tumour cell migration, invasion, and metastasis. These effects are rescued by ectopic Snail1 expression. IL-6 also stabilizes Snail1 by inducing Dub3 expression, the specific inhibitor WP1130 binds to Dub3 and inhibits the Dub3-mediating Snail1 stabilization in vitro and in vivo. Our study reveals a critical Dub3–Snail1 signalling axis in EMT and metastasis, and provides an effective therapeutic approach against breast cancer.

5 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJingyi Liu
Jingyi Liu
ZDZhibing Duan
Zhibing Duan
WGWeijie Guo
Weijie Guo
LZLei Zeng
Lei Zeng
YWYadi Wu
Yadi Wu
JSJian Shi
Jian Shi
BRD4 assembles transcriptional machinery at gene super-enhancer regions and governs the expression of genes that are critical for cancer progression. However, it remains unclear whether BRD4-mediated gene transcription is required for tumor cells to develop drug resistance. Our data show that prolonged treatment of luminal breast cancer cells with AKT inhibitors induces FOXO3a dephosphorylation, nuclear translocation, and disrupts its association with SirT6, eventually leading to FOXO3a acetylation as well as BRD4 recognition. Acetylated FOXO3a recognizes the BD2 domain of BRD4, recruits the BRD4/RNAPII complex to the CDK6 gene promoter, and induces its transcription. Pharmacological inhibition of either BRD4/FOXO3a association or CDK6 significantly overcomes the resistance of luminal breast cancer cells to AKT inhibitors in vitro and in vivo. Our study reports the involvement of BRD4/FOXO3a/CDK6 axis in AKTi resistance and provides potential therapeutic strategies for treating resistant breast cancer.

7 May 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.

1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Clinical studies have demonstrated the antitumor efficacy of covalent KRAS G12C inhibitors in treating advanced/metastatic cancers. In the current study, we report the preclinical characteristics of a specific KRAS p.G12C covalent inhibitor, glecirasib. Glecirasib exhibited high potency against KRAS G12C, along with a high level of selectivity over wild-type KRAS, HRAS, and NRAS in biochemical assays. On the cellular level, it substantially reduced downstream ERK and AKT phosphorylation, inhibited the viability of cancer cells harboring the KRAS p.G12C mutation, and demonstrated high selectivity over non-KRAS p.G12C cancer cells. Glecirasib could effectively inhibit HRAS G12C, NRAS G12C, and several G12C-inclusive KRAS double mutants that showed resistance to adagrasib. In vivo research suggested that once-daily dosing of glecirasib can robustly inhibit ERK phosphorylation for at least 24 hours and induced tumor regression in several xenograft models, including the NCI-H1373–luciferase intracranial model. Glecirasib in combination with cetuximab or JAB-3312 (sitneprotafib, a clinical-stage SHP2 inhibitor developed by Jacobio Pharma) significantly enhanced antitumor activity both in vitro and in vivo. Collectively, these results suggest that glecirasib is a potent and selective covalent inhibitor of KRAS G12C, shows potent antitumor activity as monotherapy, and synergizes with either EGFR blockade or SHP2 inhibition. A new drug application for glecirasib has been submitted in China, seeking approval for the treatment of non–small cell lung cancer, supported by a pivotal phase II single-arm study (NCT05009329). Additionally, glecirasib is being explored in clinical trials in combination with cetuximab (phase II, NCT05194995) and JAB-3312 (phase III, NCT06416410). Significance: Glecirasib potently and selectively inhibits KRAS G12C and reduces ERK and AKT phosphorylation in KRAS G12C–mutant cancer cells, further inducing cell-cycle arrest and apoptosis. Glecirasib monotherapy leads to tumor regression in KRAS G12C–mutant animal models and shows synergistic effects with cetuximab or JAB-3312 (sitneprotafib).

15 May 2025
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S6 shows IC50 values in GppNp-bound RAS and cRAF interaction assays.

15 May 2025
Verified
Other
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Glecirasib inhibited ERK phosphorylation and growth of tumors carrying the KRAS G12C mutation in vivo. A–C, PK/PD studies of a single-dose glecirasib administration in NCI-H358 lung cancer xenograft tumors bearing in the flank of mice. Dose response following a single dose of glecirasib is shown in A. Time-dependent PK/PD properties after a single dose of 30 mg/kg and 100 mg/kg glecirasib are shown in B and C, respectively. After 8 hours, glecirasib concentrations in both plasma and tumor in the 30 mg/kg group, as well as the plasma drug concentration in the 100 mg/kg group, were below the quantification limit (plasma: 1 ng/mL; tumor: 5.5 ng/g). Glecirasib concentrations in plasma and tumor tissue were quantified by LC/MS-MS, whereas p-ERK levels in tumors were measured by HTRF. Three mice per group. D–F,In vivo efficacy studies of glecirasib in CDX models: NCI-H1373 lung cancer (D), NCI-H358 lung cancer (E), and MIA PaCa-2 pancreatic cancer (F). NCI-H1373 and MIA PaCa-2 CDX models: six mice per group; NCI-H358 CDX model: eight mice per group. Glecirasib was administrated once a day orally. G and H, Tumor growth curves (G) and mice body weight curves (H) of the LUN156 lung cancer PDX model after treatment with glecirasib. Six mice per group. All data are represented as the mean ± SEM. conc., concentration; p.o., orally; QD, once a day.